Effect of pilocarpine on substance P and calcitonin gene-related peptide releases correlate with salivary secretion in human saliva and plasma

Sato, Yukie; Suzuki, Yosuke; Tatsuta, Ryosuke; Takeyama, Masaharu

doi:10.1111/jcpt.12011

Cited by 7 publications

(9 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies were published between 1998 and 2021. Most studies (Arai et al, 1998a;Arai et al, 1998b;Nakayama et al, 1998; Arai Frontiers in Pharmacology frontiersin.org , 2001;Arai et al, 2003;Arai et al, 2005;Shimizu et al, 2008;Nakashima et al, 2011;Liu et al, 2012;Matsumoto et al, 2012;Sato et al, 2013;Lee et al, 2015;Kano et al, 2016;Kumazawa et al, 2019;Noguchi et al, 2020) were from Asian countries; three publications were from European countries (Bosch et al, 2012;Miarons et al, 2016;Miarons et al, 2018); and two publications were from American countries (Marciniak et al, 2009;Fernandes et al, 2021). Seventeen publications were articles in peer-reviewed journals and three were congress abstracts.…”

Section: Characteristics Of the Included Studiesmentioning

confidence: 99%

“…Concerning study design, seven were retrospective observational studies, six were prospective observational studies, five were RCTs, and two were single-arm CTs. The sample size was <50 in four studies (Arai et al, 1998a;Nakayama et al, 1998;Shimizu et al, 2008;Kano et al, 2016), between 50 and 99 in five studies (Arai et al, 2003;Marciniak et al, 2009;Nakashima et al, 2011;Lee et al, 2015;Miarons et al, 2018) between 100 and 500 in five studies (Arai et al, 2001;Bosch et al, 2012;Matsumoto et al, 2012;Sato et al, 2013;Fernandes et al, 2021) and >500 in five studies (Arai et al, 1998b;Arai et al, 2005;Liu et al, 2012;Miarons et al, 2016;Kumazawa et al, 2019); in one study the overall sample size was not specified (Noguchi et al, 2020). The majority of the studies recruited neurological patients (10 studies on stroke (Arai et al, 1998a;Arai et al, 2001;Arai et al, 2003;Arai et al, 2005;Shimizu et al, 2008;Marciniak et al, 2009;Liu et al, 2012;Matsumoto et al, 2012;Lee et al, 2015;Kumazawa et al, 2019), one study on dementia (Bosch et al, 2012), and one on amyotrophic lateral sclerosis); in five studies participants had multiple etiologies (Nakayama et al, 1998;Nakashima et al, 2011;Miarons et al, 2016;Miarons et al, 2018;Fernandes et al, 2021).…”

Section: Characteristics Of the Included Studiesmentioning

confidence: 99%

“…Mean age of recruited patients was >65 years for all the studies, with eight studies including only elderly patients (Arai et al, 1998a;Nakayama et al, 1998;Nakashima et al, 2011;Bosch et al, 2012;Miarons et al, 2016;Fernandes et al, 2021). With regard to the pharmacological intervention, the effects of ACEi (Arai et al, 1998a;Arai et al, 1998b;Nakayama et al, 1998;Arai et al, 2001;Arai et al, 2003;Arai et al, 2005;Shimizu et al, 2008;Marciniak et al, 2009;Nakashima et al, 2011;Bosch et al, 2012;Liu et al, 2012;Matsumoto et al, 2012;Sato et al, 2013;Lee et al, 2015;Kano et al, 2016;Kumazawa et al, 2019;Fernandes et al, 2021) were analyzed in 17 studies, whereas the effects of beta-blockers (Miarons et al, 2016;Miarons et al, 2018) and DPP4i (Noguchi et al, 2020) were investigated in two and one studies, respectively.…”

Section: Characteristics Of the Included Studiesmentioning

confidence: 99%

See 2 more Smart Citations

On the potential of drug repurposing in dysphagia treatment: New insights from a real-world pharmacovigilance study and a systematic review

Battini

Rocca²,

Guarnieri³

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Background: Polypharmacy is common in patients with dysphagia. Routinely used drugs may influence swallowing function either improving or worsening it. We aimed to explore the potential effects of three commonly used drug classes on dysphagia and aspiration pneumonia through a systematic review and a real-world data analysis to probe the possibility of drug repurposing for dysphagia treatment.Material and Methods: Five electronic databases were searched. Studies on adults at risk for dysphagia, treated with Dipeptidyl-Peptidase IV Inhibitors (DPP-4i), Adrenergic Beta-Antagonists (beta-blockers), or Angiotensin-Converting Enzyme Inhibitors (ACEi), and reporting outcomes on dysphagia or aspiration pneumonia were included. A nested case/non-case study was performed on adverse events recorded in the FDA Adverse Event Reporting System (FAERS) on patients >64 years. Cases (dysphagia or aspiration pneumonia) were compared between patients only treated with Levodopa and patients who were concomitantly treated with the drugs of interest.Results: Twenty studies were included in the review (17 on ACEi, 2 on beta-blockers, and 1 on DPP-4i). Contrasting findings on the effects of ACEi were found, with a protective effect mainly reported in Asian studies on neurological patients. Beta-blockers were associated with a reduced dysphagia rate. The study on DPP-4i suggested no effect on dysphagia and an increased risk of aspiration pneumonia. The FAERS analysis showed a reduction of the risk for dysphagia/aspiration pneumonia with ACEi, beta-blockers, and DPP-4i.Conclusion: Our study explores the potential drug repurposing of ACEi, beta-blockers and DPP-4i in neurological patients with dysphagia to improve swallowing function and reduce aspiration pneumonia risk. Future randomized controlled studies should confirm these results and clarify the underlying mechanisms of action.

show abstract

Section: Characteristics Of the Included Studiesmentioning

confidence: 99%

Section: Characteristics Of the Included Studiesmentioning

confidence: 99%

Section: Characteristics Of the Included Studiesmentioning

confidence: 99%

See 1 more Smart Citation

On the potential of drug repurposing in dysphagia treatment: New insights from a real-world pharmacovigilance study and a systematic review

Battini

Rocca²,

Guarnieri³

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…Saliva is mainly produced by the parotid, submandibular and sublingual glands as well as numerous minor glands located in the submucosa of the mouth (100). Salivary glands are controlled by the autonomic nervous system, and to a lesser degree innervated by CGRP-positive fibers that evoke salivary secretion (101)(102)(103).…”

Section: Other Sources Of Cgrp For the Investigation In Migraine Pati...mentioning

confidence: 99%

CGRP and Migraine: What Have We Learned From Measuring CGRP in Migraine Patients So Far?

Kamm

2022

Front. Neurol.

View full text Add to dashboard Cite

The multi-functional neuropeptide calcitonin gene-related peptide (CGRP) plays a major role in the pathophysiology of migraine. The detection of elevated CGRP levels during acute migraine headache was the first evidence of the importance of the peptide. Since then, elevated CGRP levels have been detected not only during spontaneous and experimentally induced migraine attacks but also interictally. However, the detection of CGRP in peripheral blood shows conflicting results. In this respect, alternative detection methods are needed and have been already proposed. This article summarizes what we have learned from studies investigating CGRP in jugular and peripheral blood and reviews the latest state of research concerning the detection of CGRP in saliva and tear fluid as well as their contribution to our understanding of migraine pathophysiology.

show abstract

“…However, sialorphin expression in rat salivary glands is limited to the submandibular glands, which does not seem the case in humans, the contribution of each gland in the production of saliva opiorphin has yet to be determined. Salivary opiorphin may act on its membrane-bound target sites, i.e., NEP and/or AP-N ectopeptidases, that are present in oral sites as well as in the lower segments of the digestive axis and control salivary concentrations of circulating NEP-and/or AP-N-sensitive regulatory peptides [44][45][46] and/or modulate colonic motility via an indirect action on enkephalin-dependent opioid receptors [8]. Salivary opiorphin may also be absorbed and enter the circulation to mediate endocrine and behavioral effects [1].…”

Section: Secretion Of Opiorphin In Human Salivamentioning

confidence: 99%

Opiorphin Secretion Pattern in Healthy Volunteers: Gender Difference and Organ Specificity

Dufour¹,

Villard-Saussine²,

Mellon³

et al. 2013

Biochem Anal Biochem

View full text Add to dashboard Cite

Background: Opiorphin is an endogenous human peptide regulator of enkephalin bioavailability. It inhibits enkephalin-inactivating ectopeptidases to produce analgesia and antidepressant-like effects in standard rodent models via activation of µ and/or δ opioid pathways. Our aim was to establish the quantitative profile of secretion and distribution of this regulator in young adult volunteers. Methods: We developed a specific ELISA-based method, in tandem with RP-HPLC chromatography, to determine opiorphin levels in blood, urine, semen and milk of healthy male and female volunteers. We also investigated the presence of the mature opiorphin in tears and saliva because it was previously reported that PROL1 gene, encoding opiorphin precursor, is primarily expressed in human lachrymal and salivary glands. Results: Opiorphin circulates as an endocrine messenger in the human bloodstream at 0.3-1.1 ng/ml median ranges. Its physiological concentration under basal conditions is higher in males than in females while it is significantly lower in sixth month pregnant compared to non-pregnant volunteers. It is eliminated in the urine with a significant higher rate in men compared to women. Opiorphin is distributed, at rates 10 times higher than in plasma, in the semen of normozoospermic donors and in the milk of lactating women as both free molecular and cation mineral-binding forms. Opiorphin is secreted in tears and saliva at the highest physiological concentrations, demonstrating that salivary and lachrymal glands are the tissues of major expression and secretion of PROL1 gene mature products. Discussion: Our data, associated with database searches from human transcriptome and our previous functional findings, provide evidence that opiorphin exerts organ-specific and gender-specific functions in human physiological systems through neuroendocrine, paracrine/autocrine and/or exocrine mechanisms.

show abstract

Effect of pilocarpine on substance P and calcitonin gene-related peptide releases correlate with salivary secretion in human saliva and plasma

Cited by 7 publications

References 22 publications

On the potential of drug repurposing in dysphagia treatment: New insights from a real-world pharmacovigilance study and a systematic review

On the potential of drug repurposing in dysphagia treatment: New insights from a real-world pharmacovigilance study and a systematic review

CGRP and Migraine: What Have We Learned From Measuring CGRP in Migraine Patients So Far?

Opiorphin Secretion Pattern in Healthy Volunteers: Gender Difference and Organ Specificity

Contact Info

Product

Resources

About